Benefits
Cell-free La1 liquid partly lowered H. pylori in 20 adults
In a randomized double-blind study of 20 adults with an average age of 33 (PMID 10343133), a cell-free whey liquid made from La1 cultures, not the live bacteria, produced a partial, long-term drop in H. pylori that did not depend on changing stomach acid. One group also took prescription omeprazole 20 mg four times a day, and follow-up stomach biopsies confirmed the infection was still present. This is a small early study in people who already had an infection, so it says nothing about what La1 does for a healthy person.
Partial drop in H. pylori carriage in symptom-free volunteers
In a 2003 study of volunteers who carried H. pylori without symptoms (PMID 12697639), taking La1 often lowered how much of the bacteria was present. The drop was partial and the bacteria were not cleared. Everyone in the study was symptom-free, so the result says nothing about easing stomach complaints.
Tested in children aged 6 to 16 who carried H. pylori
The only reference cited on this page (PMID 18343637, Nutrition 2008) is a randomized multicentre trial in children aged 6 to 16 who were carrying H. pylori without symptoms. It tested cranberry juice, La1, or both, and the authors concluded only that regular intake of either may be useful in managing symptom-free colonization in children. It is a paediatric infection study, not evidence of a general gut benefit in adults.
Reduced stomach inflammation in mice (not people)
In C57BL/6 mice, La1 eased H. pylori-related stomach inflammation and lowered inflammatory signalling proteins. This is animal work only. No human study on this page measured gastritis or inflammation, so this finding should not be read as something La1 does in people.
Lactacin F: a lab-bench antimicrobial mechanism
L. johnsonii makes lactacin F, a bacteriocin that punches holes in the membranes of other bacteria in laboratory tests. This is a test-tube observation about how the strain might act. No study cited here shows that lactacin F produces any measurable benefit in people.
Suppressive vs eradicative — honest framing
In the studies, La1 partly lowered the amount of H. pylori over time but never cleared it. Does not replace standard triple/quadruple H. pylori eradication therapy. H. pylori infection is diagnosed and treated by a doctor, and nothing here is a substitute for that care.
Mechanism of action
Lactacin F bacteriocin pore formation
In laboratory tests, lactacin F forms pores in the membranes of other bacteria and disrupts them. This has been shown on the bench, not in people.
Whey-based culture supernatant activity
The 1999 human study used the liquid left after growing La1, filtered free of the live bacteria, which means the effect seen there cannot be credited to a live probiotic. Products sold as live La1 capsules or fermented milk are not the same thing that was tested in that study.
Mucus thickness enhancement
La1 has been reported to thicken the stomach's mucus layer, which would put more distance between H. pylori and the stomach lining. This comes from laboratory and animal work, not from any of the human studies cited here.
Adhesin competition with H. pylori
In laboratory work, La1 can compete for the same asialo-GM1 and sulfatide binding sites on stomach cells that H. pylori uses to attach. Whether this competition happens meaningfully in a living human stomach has not been shown.
Acid-independent suppression
The 1999 study reported that the suppression did not appear to depend on stomach acid, since it was seen with and without the acid-blocking drug omeprazole. That is one observation from a 20-person study, not an established mechanism.
Proinflammatory chemokine reduction
In mice, La1 lowered inflammatory signalling proteins in the stomach. Mouse immune findings do not transfer to people, and no human study cited here measured inflammation or any immune outcome.
Clinical trials
Michetti P, Dorta G, Wiesel PH et al.
Clinical population described in trial publication.
Michetti P, Dorta G, Wiesel PH and colleagues, Digestion 1999;60(3):203-209 (PMID 10343133). Randomized, double-blind study in 20 adults (8 women, 12 men, average age 33) infected with H. pylori. What was tested was a cell-free whey liquid made from La1 cultures, not live probiotic bacteria, and one group also received prescription omeprazole 20 mg four times daily. The authors reported a partial, acid-independent, long-term suppressive effect, and stomach biopsies confirmed the infection was still present. Twenty people is a very small study and the bacteria were never eliminated.
Frequent ingestion of La1 in asymptomatic H. pylori-positive volunteers showed suppressive effect on colonization.
Clinical population described in trial publication.
Gotteland M and Cruchet S, Journal of Antimicrobial Chemotherapy 2003;51(5):1317-1319 (PMID 12697639). Frequent intake of La1 lowered H. pylori colonization in volunteers who carried the bacteria without symptoms. The effect was a reduction in bacterial numbers only. No symptom, inflammation or immune outcomes were measured, and the bacteria were not eradicated.
Animal study in mice. Not a clinical trial and not evidence of an effect in people.
Clinical population described in trial publication.
C57BL/6 mouse model. La1 eased H. pylori-related stomach inflammation and lowered inflammatory signalling proteins. This is preclinical animal work, included for background only. No human study on this page measured gastritis or inflammation.